Collegium Pharmaceutical (COLL) Net Income towards Common Stockholders (2014 - 2026)

Collegium Pharmaceutical has reported Net Income towards Common Stockholders for 13 years, with the latest figure at -$15.1 million in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 225.6% year-over-year to -$15.1 million in Q2 2026; TTM through Jun 2026 was $47.9 million, a 32.1% increase from a year earlier, with the FY2025 full-year figure at $62.9 million, down 9.13% from the prior year.
• Net Income towards Common Stockholders was -$15.1 million for Q2 2026 at Collegium Pharmaceutical, down from $14.5 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $31.9 million in Q4 2023, with the low at -$17.4 million in Q1 2023.
• Average Net Income towards Common Stockholders over 5 years is $8.6 million, with a median of $12.3 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Net Income towards Common Stockholders surged 4415.1% in 2023, then slumped 225.6% in 2026.
• Over 5 years, Net Income towards Common Stockholders stood at -$7.2 million in 2022, then jumped by 543.67% to $31.9 million in 2023, then slumped by 60.75% to $12.5 million in 2024, then soared by 35.31% to $17.0 million in 2025, then plunged by 188.73% to -$15.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$15.1 million (Q2 2026), $14.5 million (Q1 2026), and $17.0 million (Q4 2025), per Business Quant data.